Brief: Median Technologies: New iBiopsy Clinical Development Plan For Lung Cancer Screening
Feb 16 (Reuters) - Median Technologies SA ALMDT.PA :
* IBIOPSY®: MEDIAN TECHNOLOGIES CONTINUES ITS STRONG
POSITIONING
IN EARLY-STAGE DIAGNOSIS WITH A NEW IBIOPSY® CLINICAL
DEVELOPMENT PLAN ON LUNG CANCER SCREENING (LCS)
* FIRST RESULTS FOR A PROOF OF CONCEPT ON A COHORT OF 1,800
PATIENTS ARE EXPECTED IN H2, 2021
Source text for Eikon: ID:nBw8QhCyFa
Further company coverage: ALMDT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Median Technologies SA
See all newsBrief: Median Technologies Forms Strategic Review Committee To Consider iCRO Separation, US Listing
France's Median Technologies H1 order backlog rises on demand from biopharmaceutical clients
Brief: Median Technologies H1 Revenue EUR 11.8 Million
Brief: Median Launches Eur 40 Mln Capital Raise To Fund Eyonis Rollout, Extend Runway To H1 2028
Brief: Median Technologies Reports FY Revenue EUR 23.5 Million